Carvacrol Alleviates Hyperuricemia-Induced Oxidative Stress and Inflammation by Modulating the NLRP3/NF-κB Pathwayt

References

• Becker MA, Schumacher HR Jr, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353(23):2450–2461. doi:10.1056/NEJMoa050373
   PubMed Web of Science ®Google Scholar
• Chatzipavlou M, Magiorkinis G, Koutsogeorgopoulou L, Kassimos D. Mediterranean diet intervention for patients with hyperuricemia: a pilot study. Rheumatol Int. 2014;34(6):759–762. doi:10.1007/s00296-013-2690-7
   PubMed Web of Science ®Google Scholar
• Dehlin M, Jacobsson L, Roddy E. Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nat Rev Rheumatol. 2020;16(7):380–390. doi:10.1038/s41584-020-0441-1
   PubMed Web of Science ®Google Scholar
• Ashiq K, Bajwa MA, Tanveer S, et al. A comprehensive review on gout: the epidemiological trends, pathophysiology, clinical presentation, diagnosis and treatment. JPMA. 2021;4:71.
   Google Scholar
• Chiou A, England BR, Sayles H, et al. Coexistent hyperuricemia and gout in rheumatoid arthritis: associations with comorbidities, disease activity, and mortality. Arthritis Care Res. 2020;72(7):950–958. doi:10.1002/acr.23926
   Web of Science ®Google Scholar
• Li L, Zhang Y, Zeng C. Update on the epidemiology, genetics, and therapeutic options of hyperuricemia. Am J Transl Res. 2020;12(7):3167–3181.
   PubMed Web of Science ®Google Scholar
• Martillo MA, Nazzal L, Crittenden DB. The crystallization of monosodium urate. Curr Rheumatol Rep. 2014;16(2):400. doi:10.1007/s11926-013-0400-9
   PubMed Web of Science ®Google Scholar
• Cho J, Kim C, Kang DR, Park JB. Hyperuricemia and uncontrolled hypertension in treated hypertensive patients: k-MetS Study. Medicine. 2016;95(28):28. doi:10.1097/MD.0000000000004177
   Web of Science ®Google Scholar
• Shah P, Bjornstad P, Johnson RJ. Hyperuricemia as a potential risk factor for type 2 diabetes and diabetic nephropathy. SciELO Bras. 2016;4:56.
   Google Scholar
• Zoppini G, Targher G, Chonchol M, et al. Serum uric acid levels and incident chronic kidney disease in patients with type 2 diabetes and preserved kidney function. Diabetes Care. 2012;35(1):99–104. doi:10.2337/dc11-1346
   PubMed Web of Science ®Google Scholar
• Ogura T, Matsuura K, Matsumoto Y, et al. Recent trends of hyperuricemia and obesity in Japanese male adolescents, 1991 through 2002. Metabolism. 2004;53(4):448–453. doi:10.1016/j.metabol.2003.11.017
   PubMed Web of Science ®Google Scholar
• Yokokawa H, Fukuda H, Suzuki A, et al. Association between serum uric acid levels/hyperuricemia and hypertension among 85,286 Japanese workers. J Clin Hypertens. 2016;18(1):53–59. doi:10.1111/jch.12627
   Web of Science ®Google Scholar
• Sattui SE, Gaffo AL. Treatment of hyperuricemia in gout: current therapeutic options, latest developments and clinical implications. Ther Adv Musculoskelet Dis. 2016;8(4):145–159. doi:10.1177/1759720X16646703
   PubMed Web of Science ®Google Scholar
• Benn CL, Dua P, Gurrell R, et al. Physiology of hyperuricemia and urate-lowering treatments. Front med. 2018;5:160. doi:10.3389/fmed.2018.00160
   PubMed Web of Science ®Google Scholar
• Dalbeth N, Haskard D. Mechanisms of inflammation in gout. Rheumatology. 2005;44(9):1090–1096. doi:10.1093/rheumatology/keh640
   PubMed Web of Science ®Google Scholar
• Filipe P, Haigle J, Freitas J, et al. Anti‐and pro‐oxidant effects of urate in copper‐induced low‐density lipoprotein oxidation. Eur J Biochem. 2002;269(22):5474–5483. doi:10.1046/j.1432-1033.2002.03245.x
   PubMedGoogle Scholar
• Aruoma OI, Halliwell B. Inactivation of α1‐antiproteinase by hydroxyl radicals The effect of uric acid. FEBS Lett. 1989;244(1):76–80. doi:10.1016/0014-5793(89)81166-4
   PubMed Web of Science ®Google Scholar
• Martinon F. Mechanisms of uric acid crystal‐mediated autoinflammation. Immunol Rev. 2010;233(1):218–232. doi:10.1111/j.0105-2896.2009.00860.x
   PubMedGoogle Scholar
• Busso N, Gout SA. Mechanisms of inflammation in gout. Arthritis Res Ther. 2010;12(2):1–8. doi:10.1186/ar2952
   Web of Science ®Google Scholar
• Latz E, Xiao TS, Stutz A. Activation and regulation of the inflammasomes. Nat Rev Immunol. 2013;13(6):397–411. doi:10.1038/nri3452
   PubMed Web of Science ®Google Scholar
• Szekanecz Z, Szamosi S, Kovács GE, Kocsis E, Benkő S. The NLRP3 inflammasome-interleukin 1 pathway as a therapeutic target in gout. Arch Biochem Biophys. 2019;670:82–93. doi:10.1016/j.abb.2019.01.031
   PubMed Web of Science ®Google Scholar
• Wang Z, Zhang S, Xiao Y, et al. NLRP3 inflammasome and inflammatory diseases. Oxid Med Cell Longev. 2020;2020:e45.
   Web of Science ®Google Scholar
• Chen L, Lan Z. Polydatin attenuates potassium oxonate-induced hyperuricemia and kidney inflammation by inhibiting NF-κB/NLRP3 inflammasome activation via the AMPK/SIRT1 pathway. Food Funct. 2017;8(5):1785–1792. doi:10.1039/C6FO01561A
   PubMed Web of Science ®Google Scholar
• Deng W, Yang Z, Yue H, Ou Y, Hu W, Sun P. Disulfiram suppresses NLRP3 inflammasome activation to treat peritoneal and gouty inflammation. Free Radic Biol Med. 2020;152:8–17. doi:10.1016/j.freeradbiomed.2020.03.007
   PubMed Web of Science ®Google Scholar
• Klück V, Tim L, Janssen M, et al. Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial. Lancet Rheumatol. 2020;2(5):e270–e280. doi:10.1016/S2665-9913(20)30065-5
   PubMedGoogle Scholar
• Liu X, Chen R, Shang Y, Jiao B, Huang C. Lithospermic acid as a novel xanthine oxidase inhibitor has anti-inflammatory and hypouricemic effects in rats. Chem Biol Interact. 2008;176(2–3):137–142. doi:10.1016/j.cbi.2008.07.003
   PubMed Web of Science ®Google Scholar
• Liu Y, Tang H, Liu X, et al. Frontline Science: reprogramming COX‐2, 5‐LOX, and CYP4A‐mediated arachidonic acid metabolism in macrophages by salidroside alleviates gouty arthritis. J Leukoc Biol. 2019;105(1):11–24. doi:10.1002/JLB.3HI0518-193R
   PubMed Web of Science ®Google Scholar
• Kiyani MM, Butt MA, Rehman H, et al. Antioxidant and anti-gout effects of orally administered zinc oxide nanoparticles in gouty mice. J Trace Elem Med Biol. 2019;56:169–177. doi:10.1016/j.jtemb.2019.08.012
   PubMed Web of Science ®Google Scholar
• Kiyani MM, Butt MA, Rehman H, et al. Evaluation of antioxidant activity and histopathological changes occurred by the oral ingestion of CuO nanoparticles in monosodium urate crystal-induced hyperuricemic BALB/c mice. Biol Trace Elem Res. 2000;2022:217–227.
   Google Scholar
• Malik I, Shah FA, Ali T, et al. Potent natural antioxidant carveol attenuates MCAO-stress induced oxidative, neurodegeneration by regulating the Nrf-2 pathway. Front Neurosci. 2020;14:659. doi:10.3389/fnins.2020.00659
   PubMed Web of Science ®Google Scholar
• Al Kury LT, Dayyan F, Ali Shah F, et al. Ginkgo biloba extract protects against methotrexate-induced hepatotoxicity: a computational and pharmacological approach. Molecules. 2020;25(11):2540. doi:10.3390/molecules25112540
   PubMed Web of Science ®Google Scholar
• Shah FA, Kury LA, Li T, et al. Polydatin attenuates neuronal loss via reducing neuroinflammation and oxidative stress in rat MCAO models. Front Pharmacol. 2019;10:663. doi:10.3389/fphar.2019.00663
   PubMed Web of Science ®Google Scholar
• Sharifi‐Rad M, Varoni EM, Iriti M, et al. Carvacrol and human health: a comprehensive review. Phytother Res. 2018;32(9):1675–1687. doi:10.1002/ptr.6103
   PubMed Web of Science ®Google Scholar
• Bayir AG, Kiziltan HS, Kocyigit A. Plant family, carvacrol, and putative protection in gastric cancer. In: Dietary Interventions in Gastrointestinal Diseases. Elsevier; 2019:3–18.
   Google Scholar
• Wang X, Wang C-P, Hu Q-H, et al. The dual actions of Sanmiao wan as a hypouricemic agent: down-regulation of hepatic XOD and renal mURAT1 in hyperuricemic mice. J Ethnopharmacol. 2010;128(1):107–115. doi:10.1016/j.jep.2009.12.035
   PubMed Web of Science ®Google Scholar
• Oh DR, Kim JR, Choi CY, et al. Effects of ChondroT on potassium Oxonate-induced Hyperuricemic mice: downregulation of xanthine oxidase and urate transporter 1. BMC Complement Altern Med. 2019;19(1):10. doi:10.1186/s12906-018-2415-2
   PubMed Web of Science ®Google Scholar
• Ullah U, Badshah H, Malik Z, et al. Hepatoprotective effects of melatonin and celecoxib against ethanol-induced hepatotoxicity in rats. Immunopharmacol Immunotoxicol. 2020;42(3):255–263. doi:10.1080/08923973.2020.1746802
   PubMed Web of Science ®Google Scholar
• Imran M, Shah FA, Nadeem H, et al. Synthesis and biological evaluation of benzimidazole derivatives as potential neuroprotective agents in an ethanol-induced rodent model. ACS Chem Neurosci. 2021;12(3):489–505. doi:10.1021/acschemneuro.0c00659
   PubMed Web of Science ®Google Scholar
• Mohsin Alvi A. Tariq Al Kury L, Umar Ijaz M, et al. Post-treatment of synthetic polyphenolic 1, 3, 4 oxadiazole compound A3, attenuated ischemic stroke-induced neuroinflammation and neurodegeneration. Biomolecules. 2020;10(6):816. doi:10.3390/biom10060816
   PubMed Web of Science ®Google Scholar
• Ali A, Shah FA, Zeb A, et al. NF-κB inhibitors attenuate MCAO induced neurodegeneration and oxidative stress—a reprofiling approach. Front Mol Neurosci. 2020;13:33. doi:10.3389/fnmol.2020.00033
   PubMed Web of Science ®Google Scholar
• Imran M, Al Kury LT, Nadeem H, et al. Benzimidazole containing acetamide derivatives attenuate neuroinflammation and oxidative stress in ethanol-induced neurodegeneration. Biomolecules. 2020;10(1):108. doi:10.3390/biom10010108
   PubMed Web of Science ®Google Scholar
• Iqbal S, Shah FA, Naeem K, et al. Succinamide derivatives ameliorate neuroinflammation and oxidative stress in scopolamine-induced neurodegeneration. Biomolecules. 2020;10(3):443. doi:10.3390/biom10030443
   PubMed Web of Science ®Google Scholar
• Zulfiqar Z, Shah FA, Shafique S, et al. Repurposing FDA approved drugs as JNK3 inhibitor for prevention of neuroinflammation induced by MCAO in rats. J Inflamm Res. 2020;13:1185. doi:10.2147/JIR.S284471
   PubMed Web of Science ®Google Scholar
• Rahman ZU, Al Kury LT, Alattar A, et al. Carveol a naturally-derived potent and emerging nrf2 activator protects against Acetaminophen-induced hepatotoxicity. Front Pharmacol. 2020;11:e34.
   PubMed Web of Science ®Google Scholar
• Neogi T, Jansen TL, Dalbeth N, et al. Gout classification criteria: an American College of Rheumatology/European league against rheumatism collaborative initiative. Arthritis Rheumatol. 2015;67(10):2557–2568. doi:10.1002/art.39254
   PubMed Web of Science ®Google Scholar
• Guimarães AG, Xavier MA, de Santana MT, et al. Carvacrol attenuates mechanical hypernociception and inflammatory response. Naunyn-Schmiedeberg’s Arch Pharmacol. 2012;385(3):253–263. doi:10.1007/s00210-011-0715-x
   Google Scholar
• Silva FV, Guimarães AG, Silva ER, et al. Anti-inflammatory and anti-ulcer activities of carvacrol, a monoterpene present in the essential oil of oregano. J Med Food. 2012;15(11):984–991. doi:10.1089/jmf.2012.0102
   PubMed Web of Science ®Google Scholar
• Rezaeinasab M, Benvidi A, Gharaghani S, Abbasi S, Zare HR. Electrochemical investigation of the inhibition effect of carvacrol on xanthine oxidase activity merging with theoretical studies. Process Biochem. 2019;83:86–95. doi:10.1016/j.procbio.2019.03.014
   Web of Science ®Google Scholar
• da Silva Lima M, Quintans-Júnior LJ, de Santana WA, Kaneto CM, Soares MBP, Villarreal CF. Anti-inflammatory effects of carvacrol: evidence for a key role of interleukin-10. Eur J Pharmacol. 2013;699(1–3):112–117. doi:10.1016/j.ejphar.2012.11.040
   PubMed Web of Science ®Google Scholar
• Kiyani MM, Moghul NB, Butt MA, et al. Anti-hyperuricemic effect of iron oxide nanoparticles against monosodium urate crystals induced gouty arthritis in BALB/c mice. Biol Trace Elem Res. 2021;4:56.
   Google Scholar
• Di Giovine FS, Malawista SE, Thornton E, Duff GW. Urate crystals stimulate production of tumor necrosis factor alpha from human blood monocytes and synovial cells. Cytokine mRNA and protein kinetics, and cellular distribution. J Clin Invest. 1991;87(4):1375–1381. doi:10.1172/JCI115142
   PubMed Web of Science ®Google Scholar
• Yagnik DR, Evans BJ, Florey O, Mason JC, Landis RC, Haskard DO. Macrophage release of transforming growth factor beta1 during resolution of monosodium urate monohydrate crystal-induced inflammation. Arthritis Rheum. 2004;50(7):2273–2280. doi:10.1002/art.20317
   PubMedGoogle Scholar
• Kingsbury SR, Conaghan PG, McDermott MF. The role of the NLRP3 inflammasome in gout. J Inflamm Res. 2011;4:39. doi:10.2147/JIR.S11330
   PubMedGoogle Scholar
• Coll RC, Robertson AA, Chae JJ, et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat Med. 2015;21(3):248–255. doi:10.1038/nm.3806
   PubMed Web of Science ®Google Scholar
• Youm Y-H, Nguyen KY, Grant RW, et al. The ketone metabolite β-hydroxybutyrate blocks NLRP3 inflammasome–mediated inflammatory disease. Nat Med. 2015;21(3):263–269. doi:10.1038/nm.3804
   PubMed Web of Science ®Google Scholar
• Guma M, Ronacher L, Liu-Bryan R, Takai S, Karin M, Caspase CM. 1-independent activation of interleukin-1beta in neutrophil-predominant inflammation. Arthritis Rheum. 2009;60(12):3642–3650. doi:10.1002/art.24959
   PubMedGoogle Scholar
• Martinon F, Pétrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006;440(7081):237–241. doi:10.1038/nature04516
   PubMed Web of Science ®Google Scholar
• Gout TR. Novel therapies for treatment of gout and hyperuricemia. Arthritis Res Ther. 2009;11(4):1–11.
   Web of Science ®Google Scholar
• Pillinger MH, Mandell BF Therapeutic approaches in the treatment of gout. Sem Arthritis Rheumatism. 2020;50(3S):S24–S30.
   PubMed Web of Science ®Google Scholar
• Choi N, Yang G, Jang JH, et al. Loganin alleviates gout inflammation by suppressing nlrp3 inflammasome activation and mitochondrial damage. Molecules. 2021;26(4):1071. doi:10.3390/molecules26041071
   PubMed Web of Science ®Google Scholar
• Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity: description and guidelines for prevention in patients with renal insufficiency. Am J Med. 1984;76(1):47–56. doi:10.1016/0002-9343(84)90743-5
   PubMed Web of Science ®Google Scholar
• Han B, Gong M, Li Z, Qiu Y, Zou Z. NMR-based metabonomic study reveals intervention effects of polydatin on potassium oxonate-induced hyperuricemia in rats. Oxid Med Cell Longev. 2020;2020:1–10. doi:10.1155/2020/6943860
   Web of Science ®Google Scholar
• Ahmadvand H, Tavafi M, Asadollahi V, et al. Protective effect of carvacrol on renal functional and histopathological changes in gentamicin-induced-nephrotoxicity in rats; 2016.
   Google Scholar
• Hilmi B, Asmahan M, Rosman A. Use of newly available febuxostat in a case of chronic tophaceous gout contraindicated to allopurinol and probenecid. Med J Malaysia. 2012;67(1):125.
   PubMedGoogle Scholar